Sign up for our daily briefing
Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.
Stay on top of the latest market trends
Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.
Sports news worthy of your time
Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.
Tech news worthy of your time
Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.
Get the inside stories
Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Want a daily digest of the top Denver news?
Get a daily digest of the most important stories affecting your hometown with Axios Denver
Want a daily digest of the top Des Moines news?
Get a daily digest of the most important stories affecting your hometown with Axios Des Moines
Want a daily digest of the top Twin Cities news?
Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities
Want a daily digest of the top Tampa Bay news?
Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay
Want a daily digest of the top Charlotte news?
Get a daily digest of the most important stories affecting your hometown with Axios Charlotte
Rep. Chris Collins. Photo: Bill Clark/CQ Roll Call
Rep. Chris Collins (R-N.Y.) is resigning ahead of a hearing Tuesday in which he is expected to change his "not guilty" plea in a criminal insider trading case, Speaker Nancy Pelosi's office confirmed Monday.
Context: In August 2018, Collins was arrested in connection with an alleged insider trading scheme involving Innate Immunotherapeutics, an Australian drug company whose board he sat on for years. Prosecutors allege that Collins, the first congressman to endorse President Trump in 2016, received a tip about about a failed clinical trial involving the company's only product. He then allegedly called his son Cameron, who sold off shares of Innate stock the next day.